Generic and specialty pharmaceuticals Mylan has introduced its pressurised metered-dose inhaler (pMDI), Sirdupla, in the UK.

Sirdupla is a generic version of GlaxoSmithKline’s (GSK) Seretide Evohaler (salmeterol xinafoate/fluticasone propionate), which is indicated to treat or prevent symptoms of asthma in adults.

Mylan president Rajiv Malik said: "Mylan is excited to be the first company to offer adult asthma patients in the UK the generic version of Seretide Evohaler, delivering on our mission to increase access to high-quality medicine.

"Sirdupla represents a significant advancement for the company that both strengthens our respiratory portfolio and pipeline."

"Sirdupla represents a significant advancement for the company that both strengthens our respiratory portfolio and pipeline, and further demonstrates our ability to successfully execute on one of our key strategic growth drivers."

Sirdupla is a daily maintenance pressurised metered-dose inhaler that is available in 125/25mcg and 250/25 mcg with 120 doses.

3M Drug Delivery Systems will manufacture the generic version of GSK’s asthma therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mylan said that it is the first firm to sell a generic version of the UK’s number one prescribed long-acting beta2-agonist plus inhaled corticosteroid pressurised metered-dose inhaler asthma therapy.

3M Drug Delivery Systems general manager and president Cindy Kent said: "3M will fill, assemble and package Sirdupla at 3M’s manufacturing facility in Loughborough, UK. By partnering with Mylan, 3M has taken an important step forward in the generics space."

Mylan has a portfolio of around 1,400 generic pharmaceuticals and several brand medications. It also provides a wide range of antiretroviral therapies, including for HIV/AIDS, in developing countries.